Have a feature idea you'd love to see implemented?
Let us know!
SUPN Supernus Pharmaceuticals Inc
Price (delayed)
$35.43
Market cap
$1.96B
P/E Ratio
32.81
Dividend/share
N/A
EPS
$1.08
Enterprise value
$1.95B
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for
Highlights
The company's net income has surged by 133% YoY
The EPS has surged by 130% year-on-year
Key stats
What are the main financial stats of SUPN
Market
Valuations
Earnings
Shares outstanding
55.22M
Market cap
$1.96B
Enterprise value
$1.95B
Price to earnings (P/E)
32.81
Price to book (P/B)
1.94
Price to sales (P/S)
3
EV/EBIT
26.96
EV/EBITDA
12.55
EV/Sales
3
Revenue
$651.97M
Gross profit
$580.54M
Net income
$59.71M
EBIT
$72.48M
EBITDA
$155.72M
Free cash flow
$172.03M
Per share
Balance sheet
Liquidity
EPS
$1.08
EPS diluted
$1.07
Free cash flow per share
$3.12
Book value per share
$18.28
Revenue per share
$11.82
TBVPS
$12.43
Total assets
$1.34B
Total liabilities
$335.55M
Debt
$28.93M
Equity
$1.01B
Working capital
$348.5M
Debt to equity
0.03
Current ratio
2.2
Quick ratio
1.88
Net debt/EBITDA
-0.02
Margins
Efficiency
Dividend
EBITDA margin
23.9%
Gross margin
89%
Net margin
9.2%
Operating margin
8.5%
Return on assets
4.6%
Return on equity
6.3%
Return on invested capital
24.3%
Return on capital employed
6.9%
Return on sales
11.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SUPN stock price
How has the Supernus Pharmaceuticals stock price performed over time
Intraday
-0.95%
1 week
-2.05%
1 month
-1.91%
1 year
29.17%
YTD
22.43%
QTD
13.63%
Financial performance
How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$651.97M
Gross profit
$580.54M
Operating income
$55.64M
Net income
$59.71M
Gross margin
89%
Net margin
9.2%
SUPN's operating income has soared by 137% from the previous quarter and by 103% YoY
The company's net income has surged by 133% YoY
The company's operating margin has surged by 130% QoQ and by 89% YoY
The net margin has soared by 119% year-on-year
Growth
What is Supernus Pharmaceuticals's growth rate over time
Valuation
What is Supernus Pharmaceuticals stock price valuation
P/E
32.81
P/B
1.94
P/S
3
EV/EBIT
26.96
EV/EBITDA
12.55
EV/Sales
3
The EPS has surged by 130% year-on-year
The stock's price to earnings (P/E) is 71% less than its 5-year quarterly average of 113.7
SUPN's price to book (P/B) is 14% more than its last 4 quarters average of 1.7 and 2.1% more than its 5-year quarterly average of 1.9
Supernus Pharmaceuticals's equity has increased by 10% YoY and by 5% QoQ
The P/S is 11% above the 5-year quarterly average of 2.7 and 11% above the last 4 quarters average of 2.7
Supernus Pharmaceuticals's revenue has increased by 7% YoY and by 3.5% from the previous quarter
Efficiency
How efficient is Supernus Pharmaceuticals business performance
The return on assets has surged by 171% year-on-year
The company's return on equity has surged by 125% YoY
SUPN's return on invested capital has surged by 94% year-on-year and by 59% since the previous quarter
The return on sales has surged by 88% since the previous quarter and by 66% year-on-year
Dividends
What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SUPN.
Financial health
How did Supernus Pharmaceuticals financials performed over time
The quick ratio has soared by 58% YoY and by 16% from the previous quarter
SUPN's current ratio is up by 41% year-on-year and by 15% since the previous quarter
The debt is 97% smaller than the equity
Supernus Pharmaceuticals's debt to equity has decreased by 25% YoY
The debt is down by 15% year-on-year and by 4.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.